OBJECTIVE： To evaluate the efficacy and safety of cerebrolysin in adjuvant treatmenut of acute cerebral infarction systematically， and to provide evidence-based reference in clinic. METHODS： Retrieved from SCI， Cochrane Library， EMBase， PubMed， CJFD， VIP and Wanfang Database， RCTs about cerebrolysin combined with routine plan （trial group） vs. routine plan alone or combined with placebo （control group） in adjuvant treatment of acute cerebral infarction were collected. After data extraction and quality evaluation by using Cochrane systematic review manual 5.1.0， Meta-analysis was conducted by using Rev Man 5.2 statistical software. RESULTS： A total of 20 RCTs were included， involving 3 313 patients. Meta-analysis showed that NIHSS score [MD＝－1.77， 95％CI（－2.33，－1.21），P＜0.001]， response rate [OR＝2.85， 95％CI（1.75，4.63），P＜0.001] and Barthel index （BI） score [MD＝7.30，95％CI（3.48，11.13），P＜0.001] in trial group were significantly higher than control group， with statistical significance. There was no statistical significance in disability rate [OR＝0.46，95％CI（0.20，1.03），P＝0.06]， mortality [OR＝0.79， 95％CI（0.52，1.19），P＝0.25]， the incidence of ADR [OR＝1.04，95％CI（0.85，1.27），P＝0.72] or the incidence of severe ADR [OR＝0.01， 95％CI（－0.02，0.04），P＝0.51] between 2 groups. CONCLUSIONS： Cerebrolysin is good for adjanctive therapy of acute cerebral infarction， can significantly improve neurologic impairment and life quality and dosen’t increase the incidence of ADR.